A healthcare provider should monitor labs and symptoms closely
Administration: Once-weekly injection
United European Gastroenterol J 2023
While the primary concern with serotonin syndrome involves combinations of medications that directly increase serotonin levels, healthcare providers remain vigilant and monitor for symptoms whenever medications affecting serotonin are used together
Reduced Risk of Cardiovascular Disease: Studies have shown that semaglutide not only helps manage diabetes but also reduces the risk of major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction, or nonfatal stroke in patients with established cardiovascular disease [8]
Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
